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SUMMARY. Rapid virologic response (RVR) and complete
early virologic response (cEVR) are associated with sustained
virologic response to hepatitis C virus (HCV) therapy. We
retrospectively examined baseline and on-treatment factors
associated with RVR (HCV RNA undetectable at week 4) and
cEVR (HCV RNA undetectable at week 12, regardless of
week 4 response). The analysis comprised 1550 HCV
genotype-1 patients from ﬁve clinical trials, including three
enriched with difﬁcult-to-treat populations, randomized to
peginterferon alfa-2a 180 lg/week plus ribavirin 1000–
1200 mg/day. Overall, 15.6% achieved RVR and 54.0%
achieved cEVR. Baseline factors predictive of RVR were ser-
um HCV RNA £ 400 000 IU/mL (OR: 7.34; P < 0.0001),
alanine aminotransferase >3 · ULN (OR: 2.01; P <
0.0001), non-cirrhotic status (OR: 1.92; P = 0.0087),
age £ 40 years (OR: 1.56; P = 0.0085), white non-Latino
ethnicity (OR: 1.41; P = 0.0666) and individual study
(P < 0.0001). These factors plus body mass index £ 27 kg/
m
2 were predictive of cEVR. After adjusting for these factors,
mean on-treatment ribavirin dose >13 mg/kg/day was
predictive of RVR (OR: 1.69; P = 0.005) and cEVR (OR:
1.24; P = 0.09), whereas peginterferon alfa-2a dose reduc-
tion was not. Greater decreases in haematologic parameters
were observed in patients who achieved cEVR compared
with patients who did not. In conclusion, several baseline
and on-treatment factors were associated with RVR and
cEVR to peginterferon alfa-2a plus ribavirin in difﬁcult-
to-treat HCV genotype-1 patients, providing important
prognostic information on the antiviral response in a patient
cohort that is reﬂective of the general chronic hepatitis C
population.
Keywords: chronic hepatitis C, on-treatment, pre-treatment,
sustained virologic response.
INTRODUCTION
The recommended treatment for chronic hepatitis C (CHC)
patients is combination therapy with pegylated interferon
plus ribavirin. The goal of this treatment is a sustained
virologic response (SVR), deﬁned as the absence of detectable
viral ribonucleic acid (RNA) at 6 months after the end of
treatment. Despite improvements that have increased SVR
rates, treating CHC remains a challenge in certain popula-
tions such as those patients infected with hepatitis C virus
(HCV) genotype 1, with high viral load, cirrhosis or of
African American race/ethnicity [1–3].
In a registration trial of peginterferon alfa-2a plus ribavi-
rin, patients infected with HCV genotype 1 achieved an
optimal SVR rate of 52% after 48 weeks of treatment [1].
Given the signiﬁcant side-effects and healthcare costs asso-
ciated with interferon therapies, identifying patients who are
less likely to respond is highly desirable. Studies have dem-
onstrated that early antiviral response is predictive of a SVR
[4]. Patients who failed to achieve a complete early virologic
response (cEVR) (deﬁned as undetectable HCV RNA after
12 weeks of treatment) or a partial EVR (pEVR, deﬁned as
a ‡ 2-log10 decrease from baseline in HCV RNA after
12 weeks of treatment) had a lower likelihood of achieving
Abbreviations: ALT, alanine aminotransferase; BMI, body mass
index; cEVR, complete early virologic response; CHC, chronic
hepatitis C; CI, conﬁdence interval; EVR, early virologic response;
HCV, hepatitis C virus; ITT, intent-to-treat; OR, odds ratio; RNA,
ribonucleic acid; RVR, rapid virologic response; SVR, sustained
virologic response; ULN, upper limit of normal.
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Rapid virologic response (RVR), deﬁned as undetectable HCV
RNA after 4 weeks of treatment [8], was found to be the
single best predictor of SVR in HCV genotype 1-infected
patients treated with peginterferon alfa-2a plus ribavirin [8].
Baseline factors that have been shown to predict SVR to
peginterferon alfa-2a plus ribavirin include HCV genotype
(other than type 1), age (£40 years) and body weight
(£75 kg) [6]. Identifying factors that predict RVR and cEVR
should further reﬁne CHC treatment regimens. In patients
infected with HCV genotype 1 and treated with peginterferon
alfa-2a plus ribavirin for 24 weeks, baseline factors associ-
ated with RVR included lower viral load, absence of cirrho-
sis/bridging ﬁbrosis and HCV genotype 1b [8]. Lower viral
load was also associated with EVR/cEVR in patients treated
with peginterferon alfa-2b plus ribavirin [9]. Recent evi-
dence suggests that changes in haematologic parameters
may be associated with virologic response to therapy [10].
Patients with a null response to peginterferon alfa-2a plus
ribavirin demonstrated a smaller reduction in haematologic
parameters than patients who achieved full virologic
response, suggesting a systemic resistance to treatment [10].
Available data on the factors associated with achieving
RVR and cEVR in difﬁcult-to-treat HCV genotype 1-infected
patients treated with a standard regimen, consisting of
peginterferon alfa-2a 180 lg/week plus ribavirin 1000 or
1200 mg/day for 48 weeks, is limited. Identifying these
factors may provide information to optimize and/or indi-
vidualize the treatment of HCV genotype 1-infected patients,
thus improving antiviral response. This is of particular
importance because these difﬁcult to treat populations have
a high prevalence of HCV infection and comprise a large
proportion of the HCV-infected population in the United
States [11]. We, therefore, retrospectively analysed the data
from ﬁve large clinical trials, three of which were enriched
with difﬁcult-to-treat patients, to examine the baseline and
on-treatment factors associated with a RVR and cEVR to
treatment with peginterferon alfa-2a plus ribavirin.
MATERIALS AND METHODS
Patients
The analysis population consisted of all patients from ﬁve
clinical trials who were infected with HCV genotype 1 (mono
infection) and randomized to treatment for 48 weeks with
subcutaneous peginterferon alfa-2a (Pegasys
 ; Roche, Nut-
ley, NJ, USA; 180 lg/week) plus oral ribavirin (Copegus
 ;
Roche, Nutley, NJ, USA; 1000 or 1200 mg/day)
[1,3,6,12,13]. Three of these trials were enriched with dif-
ﬁcult-to-treat patients, including one trial in which all 189
patients had high viral load (>800 000 IU/mL) at baseline
(ClinicalTrials.gov Identiﬁer: NCT00107653) [12]; one trial
in which 78 of 106 patients (74%) were of black race [3];
and one trial in which 268 of 567 patients (47%) were
of white Latino ethnicity (ClinicalTrials.gov Identiﬁer:
NCT00087607) [13].
Study design
EVR was originally deﬁned as cEVR (HCV RNA undetectable
at week 12) or pEVR (HCV RNA detectable but >2 log
decrease at week 12) regardless of week 4 RNA level. In this
study, we investigated RVR (RNA undetectable at week 4)
and cEVR (RNA undetectable at week 12, regardless of week
4 response). Patients with missing HCV RNA measurements
at week 4 (or week 12), regardless of reason, were consid-
ered non-responders (non-RVR [or non-cEVR]) in the intent-
to-treat (ITT) efﬁcacy analyses of virologic end-points. There
were small variations between studies in the detection limits
for HCV RNA. Undetectable levels were deﬁned as HCV RNA
<28 IU/mL in one study (Roche High Pure System/COBAS
 
TaqMan
  HCV Monitor Test) [14], <60 IU/mL in another
study (Roche Amplicor polymerase chain reaction [PCR]
assay) [12] and <50 IU/mL in the remaining three studies
(Roche Amplicor PCR assay) [1,3,6].
Statistical analysis
Baseline and demographic factors used in stepwise multiple
logistic regression analyses included age (£40 vs >40 years),
sex, race/ethnicity (white non-Latino vs other), body mass
index (BMI; £27 vs >27 kg/m
2), baseline alanine amino-
transferase (ALT) quotient (£3 vs >3 · upper limit of nor-
mal [ULN]), serum HCV RNA concentration (£400 000 vs
>400 000 IU/mL), cirrhosis classiﬁcation (cirrhotic vs non-
cirrhotic) and individual study. The ﬁnal model was based
on the stepwise multiple variable logistic regression. Factors
that had a P < 0.1 from the univariate analysis were
allowed to enter the multiple regression model and factors
with an adjusted P < 0.2 were kept in the model. Wald chi-
square conﬁdence intervals (CI) and P-values were used for
testing the effects; P £ 0.2 indicated signiﬁcant factors that
remained in the ﬁnal model. To account for differences
between the studies, each individual study was forced into
the model as a stratiﬁcation factor regardless of its signiﬁ-
cance level. Odds ratios (OR) and 95% CI were calculated for
the independent predictive factors.
Additional multiple variable logistic regression analyses
included adjusting for all individually identiﬁed signiﬁcant
baseline prognostic factors and investigating the association
of two on-treatment characteristics with RVR and cEVR:
average daily exposure to ribavirin (£13 vs >13 mg/kg) and
peginterferon alfa-2a dose reductions (yes vs no).
Neutrophil counts, platelet counts and hemoglobin con-
centrations were assessed to determine if there were any
associations between virologic and haematologic responses
in these patients. Changes from baseline in these haemato-
logic parameters were compared at weeks 4 and 12 in the
RVR vs the non-RVR group, and in the cEVR vs the
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140 M. Rodriguez-Torres et al.non-cEVR group. Haematologic changes result from the
systemic effects of peginterferon and ribavirin and, therefore,
can serve as indirect (surrogate) measures of host responses
to interferons and may also reﬂect drug exposure and
adherence.
RESULTS
Baseline characteristics
Patient demographics and characteristics at baseline are
shown in Table 1. Of the 1550 patients treated with
peginterferon alfa-2a plus ribavirin, 242 (15.6%) patients
achieved RVR and 837 (54.0%) patients achieved cEVR
(Table 1). The proportion of patients in the individual trials
with a RVR ranged from 7.4% to 22.6%, while the pro-
portion of patients with a cEVR ranged from 34.0% to
64.3% (Fig. 1). Patient baseline characteristics as a func-
tion of RVR and cEVR status and the P-values from the
univariate analyses are presented in Table 2. In general,
the patient characteristics that were more likely to be
associated with achievement of RVR and cEVR were
similar.
Patient disposition
Overall, a total of 16 patients (1%) and 40 patients (2.6%)
withdrew from the study due to safety reasons by weeks 4
and 12, respectively. Seventeen patients (1.1%) and 44
patients (2.8%) withdrew due to non-safety reasons by
weeks 4 and 12, respectively. Adverse events leading to
withdrawal by week 4 included anaemia, chest pain, fatigue,
rash, tongue oedema, headache, gastrointestinal events such
as nausea and abdominal pain, and psychiatric effects such
as aggression, suicide ideation and emotional instability.
Multiple logistic regression analysis
The results of the multiple logistic regression analyses
demonstrated that baseline factors independently associated
with a RVR included serum HCV RNA £400 000 IU/mL
(OR: 7.34; 95% CI 5.29–10.19; P < 0.0001), ALT quotient
Table 1 Patient demographics, baseline characteristics and average daily ribavirin dose for the total population, rapid virologic
response group (RVR) and complete early virologic response group (cEVR)
Characteristic Total RVR cEVR
Number of patients, n (%)* 1550 (100.0) 242 (15.6) 837 (54.0)
Sex, n (%)

Male 1031 (66.5) 162 (66.9) 549 (65.6)
Age, years, mean ± SD 45.3 ± 9.24 42.2 ± 9.99 43.7 ± 9.31
Age £40 years, n (%)
 438 (28.3) 100 (41.3) 298 (35.6)
Weight, kg, mean ± sd 82.4 ± 18.1 78.2 ± 16.1 81.1 ± 17.8
Weight £75 kg, n (%)
 567 (36.6) 104 (43.0) 331 (39.5)
BMI, kg/m
2, mean ± SD 28.0 ± 5.35 26.6 ± 4.46 27.5 ± 5.23
BMI £27 kg/m
2, n (%)
 734 (47.4) 140 (57.9) 435 (52.0)
Race, n (%)

White non-Latino 1049 (67.7) 179 (74.0) 611 (73.0)
White Latino 296 (19.1) 39 (16.1) 141 (16.8)
Black 154 (9.9) 8 (3.3) 47 (5.6)
Other 51 (3.3) 16 (6.6) 38 (4.5)
ALT, n (%)

ALT quotient >3 · ULN 362 (23.4) 79 (32.6) 225 (26.9)
HCV RNA, log10, mean ± sd 6.2 ± 0.71 5.5 ± 0.92 6.1 ± 0.79
Serum HCV RNA
£400 000 IU/mL, n (%)
 296 (19.1) 125 (51.7) 222 (26.5)
£800 000 IU/mL, n (%) 476 (30.7) 154 (32.4) 310 (65.1)
Cirrhotic classiﬁcation, n (%)

Cirrhotic 240 (15.5) 25 (10.3) 103 (12.3)
On-treatment average daily ribavirin dose, n (%)

£13 mg/kg 487 (31.4) 50 (20.7) 251 (30.0)
>13 mg/kg 1063 (68.6) 192 (79.3) 586 (70.0)
ALT, alanine aminotransferase; BMI, body mass index; SD, standard deviation; ULN, upper limit normal. *% Calculated relative
to the total population.
% Calculated relative to RVR or cEVR groups.
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rapid virologic response (RVR) or
complete early virologic response
(cEVR) in individual studies of
peginterferon alfa-2a plus ribavirin—
intent-to-treat.
Table 2 Baseline characteristics and
average daily ribavirin dose as a function
of rapid virologic response (RVR) and
complete early virologic response (cEVR)
Characteristic
RVR cEVR
n (%) P-value
 n (%) P-value

Number of patients* 242 (15.6) 837 (54.0)
Sex
Male 162 (15.7) 0.8659 549 (53.2) 0.4235
Female 80 (15.4) 288 (55.5)
Age
Age £40 years 100 (22.8) <0.0001 298 (68.0) <0.0001
Age >40 years 142 (12.8) 539 (48.5)
Weight
Weight £75 kg 104 (18.3) 0.0268 331 (58.4) 0.0095
Weight >75 kg 138 (14.0) 506 (51.5)
BMI
BMI £27 kg/m
2 140 (19.1) 0.0009 435 (59.3) 0.0001
BMI >27 kg/m
2 102 (12.8) 393 (49.3)
Race
White non-Latino 179 (17.1) 0.0268 611 (58.2) <0.0001
White Latino 39 (13.2) 141 (47.6)
Black 8 (5.2) 47 (30.5)
Other 16 (31.4) 38 (74.5)
ALT
ALT quotient £3 · ULN 163 (13.7) 0.0002 612 (51.5) 0.0004
ALT quotient >3 · ULN 79 (21.8) 225 (62.2)
HCV RNA
Serum HCV RNA
£400 000 IU/mL
125 (42.2) <0.0001 222 (75.0) <0.0001
Serum HCV RNA
>400 000 IU/mL
117 (9.3) 615 (49.1)
Cirrhotic classiﬁcation
Non-cirrhotic 217 (16.6) 0.0167 734 (56.0) 0.0002
Cirrhotic 25 (10.4) 103 (42.9)
On-treatment average daily ribavirin dose
£13 mg/kg/day 50 (10.7) 0.0001 251 (47.7) <0.0001
>13 mg/kg/day 192 (17.7) 586 (57.2)
ALT, alanine aminotransferase; BMI, body mass index; ULN, upper limit normal.
*% Calculated relative to the total population (n = 1550).
P-value from univar-
iate analysis.
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142 M. Rodriguez-Torres et al.>3 · ULN (OR: 2.01; 95% CI 1.43–2.81; P < 0.0001), non-
cirrhotic status (OR: 1.92; 95% CI 1.18–3.13; P = 0.0087),
age £40 years (OR: 1.56; 95% CI 1.12–2.16; P = 0.0085),
white non-Latino race (OR: 1.41; 95% CI 0.98–2.03;
P = 0.0666) and individual study (P < 0.0001). The same
independent factors were associated with a cEVR in this
analysis: baseline serum HCV RNA £400 000 IU/mL (OR:
2.81;95%CI2.07–3.81;P < 0.0001),non-cirrhoticstatusat
baseline (OR: 1.95; 95% CI 1.43–2.65; P < 0.0001), age
£40 years (OR: 1.81; 95% CI 1.41–2.34; P < 0.0001),
baseline ALT quotient >3 · ULN (OR: 1.61; 95% CI 1.24–
2.09; P = 0.0003), white non-Latino race (OR: 1.59; 95% CI
1.24–2.04; P = 0.0002) and individual study (P < 0.0001).
In addition, BMI (£27 vs >27 kg/m
2) was associated with a
cEVR in this analysis (OR: 1.21; 95% CI 0.97–1.50;
P = 0.0925). In this report we deﬁned HCV RNA
<400 000 IU/mL as low viral load. However, similar results
were obtained when the analysis was repeated with higher
HCV RNA cut-off levels (£600 000 vs >60 000 IU/mL and
£800 000 vs >800 000 IU/mL). Also, similar results were
also obtained when the analysis was repeated using different
BMI cut-off levels (>25 vs£25 kg/m
2 and>30vs £30 kg/m
2)
[M. Rodriguez-Torres, L.J. Jeffers, M.Y. Sheikh, L. Rossaro,
V.A. Sey, F.M. Hamzeh and P. Martin, unpublished data].
After adjusting for signiﬁcant risk factors in the baseline
characteristics model (Table 3), multiple logistic regression
analysis showed that compared with an average on-treat-
ment daily ribavirin dose of £13 mg/kg, an average
on-treatment daily ribavirin dose of >13 mg/kg was a pre-
dictor of RVR (OR: 1.69; 95% CI 1.17–2.43; P = 0.0049)
and cEVR (OR: 1.24; 95% CI 0.97–1.59; P = 0.0907). BMI
was associated with cEVR before, but was not after, adjust-
ing for ribavirin exposure. BMI was not associated with RVR
(Table 3). In contrast, peginterferon alfa-2a dose reduction
(yes vs no) was not a predictor of RVR or cEVR.
Haematologic effects of peginterferon plus ribavirin
The association of other host pharmacodynamic effects of
peginterferon and ribavirin with antiviral activity was
investigated (Table 4). In the RVR and non-RVR groups,
mean changes in neutrophil counts at weeks 4 and 12
decreased from baseline to a similar extent with no difference
observed between the groups. In the cEVR and non-cEVR
groups, mean changes in neutrophil counts at weeks 4 and
12 also decreased from baseline; however, the cEVR group
had a greater decrease in neutrophil counts at week 12 than
the non-cEVR group (P = 0.0003). Platelet counts decreased
from baseline at weeks 4 and 12 in all groups although the
changes were not signiﬁcant. Mean haemoglobin concen-
trations also decreased between weeks 4 and 12 in all
groups. The decrease from baseline to week 12 in the cEVR
group was greater than that in the non-cEVR group
(P = 0.0160). In the univariate analysis, body weight and
on-treatment drug exposure were both associated with RVR
and cEVR. The inﬂuence of these factors on the observed
decreases in haematologic parameters between the response
and non-response groups was analysed. After adjusting for
body weight and on-treatment drug exposure, the decrease
from baseline to week 12 in neutrophil counts and haemo-
globin concentrations in the cEVR group compared with the
non-cEVR group remained signiﬁcant (P = 0.0008 and
Table 3 Summary of multiple logistic regression analysis for baseline factors and average daily ribavirin dose predictive of
rapid virologic response (RVR) and complete early virologic response (cEVR)adjusting for signiﬁcant baseline prognostic factors
Factor
RVR cEVR
OR (95% CI) P-value* OR (95% CI) P-value*
Race
White non-Latino vs other 1.45 (1.00–2.08) 0.0474 1.61 (1.25–2.06) 0.0002
Age
£40 vs >40 years 1.51 (1.08–2.09) 0.0145 1.81 (1.40–2.32) <0.0001
Baseline ALT quotient
>3 vs £3 · ULN 2.06 (1.47–2.89) <0.0001 1.61 (1.24–2.10) 0.0003
Baseline serum HCV RNA
£400 000 vs >400 000 IU/mL 7.25 (5.23–10.07) <0.0001 2.81 (2.07–3.82) <0.0001
Cirrhosis
Non-cirrhotic vs cirrhotic 1.94 (1.19–3.17) 0.0077 1.96 (1.44–2.68) <0.0001
Individual study <0.0001 <0.0001
Average daily ribavirin dose

>13 mg/kg vs £13 mg/kg) 1.69 (1.17–2.43) 0.0049 1.24 (0.97–1.59) 0.0907
ALT, alanine aminotransferase; CI, conﬁdence intervals; OR, odds ratios; ULN, upper limit normal. *A signiﬁcance level of
P < 0.1 was used to qualify entrance into the multiple logistic regression model, and factors with P £ 0.2 were allowed to stay
in the ﬁnal model. Study was forced into the model, regardless of its signiﬁcance.
On-treatment average daily ribavirin dose.
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Factors associated with RVR and cEVR 143P = 0.0179, respectively); the decrease in platelet counts
remained non-signiﬁcant (P = 0.2093) [M. Rodriguez-
Torres, L.J. Jeffers, M.Y. Sheikh, L. Rossaro, V.A. Sey, F.M.
Hamzeh and P. Martin, unpublished data]. The results in the
RVR and non-RVR groups also remained unchanged. This
suggests that body weight and on-treatment drug exposure
were not confounding factors in the observed haematologic
changes between the response and non-response groups.
DISCUSSION
The response to antiviral therapy in HCV-infected patients is
heterogeneous and, despite increases in SVR rates, treatment
outcomes with peginterferon alfa-2a plus ribavirin are not
optimal in certain patient populations and might still be
improved [1,2]. Monitoring the early antiviral response to
therapy can help identify those patients who are less likely to
achieve SVR and therefore provide critical information for
the overall management of patients with CHC.
Both RVR and cEVR are associated with the achievement
of SVR in patients with CHC [15]. Identifying the baseline
and on-treatment factors, both virus and patient related,
that are associated with RVR and cEVR to therapy with
peginterferon alfa-2a plus ribavirin may help predict a
patients response to treatment, as well as provide important
information that can be used to improve viral outcomes [15–
17]. For example, the modiﬁcation of baseline and/or
on-treatment factors, such as drug dose, may help increase
the likelihood of successful response to therapy. Further-
more, early identiﬁcation of those patients who are unlikely
to achieve RVR or cEVR may help to reduce unnecessary
healthcare expenses and limit the side-effects associated with
drug exposure.
The analysis presented here demonstrated that several
patient characteristics, including lower serum HCV RNA,
higher ALT quotient, absence of cirrhosis, younger age and
white non-Latino race/ethnicity were associated with suc-
cessful achievement of RVR and cEVR in patients infected
with HCV genotype 1. In addition, lower BMI was associated
with achieving cEVR. The effects of peginterferon-alfa 2a
dose and ribavirin dose on RVR and cEVR were also analy-
sed. Ribavirin dose was a predictor of RVR and cEVR,
whereas peginterferon-alfa 2a dose or dose reduction was
not. This ﬁnding is in agreement with previous studies that
evaluated the effect of ribavirin dose reductions on virologic
response rates in HCV genotype 1-infected patients [18]. Our
analysis showed that, when combined with peginterferon
alfa-2a 180 lg/week, higher daily on-treatment ribavirin
exposure increased the likelihood of achieving RVR and
cEVR, even in difﬁcult-to-treat patients infected with HCV
genotype 1. Speciﬁcally, ribavirin exposure >13 vs £13 mg/
kg/day was associated with a greater proportion of patients
achieving RVR and cEVR (17.7% vs 10.7% and 57.2% vs
47.7%, respectively). Further analysis to determine the effect
of average on-treatment daily ribavirin dose on the likeli-
hood of RVR and cEVR suggested that a linear relationship
existed up to 12 and 10 mg/kg/day, respectively, after
which the effect remained relatively constant (data not
shown). However, cut-off points could not be identiﬁed since
no clear inﬂection points were obtained. Individual study
was also found to be predictive of RVR and cEVR even after
adjusting for the effects of known factors such as Latino
Table 4 Changes in neutrophil counts, platelet counts and haemoglobin concentration at weeks 4 and 12 in patients treated
with peginterferon alfa-2a plus ribavirin
RVR Non-RVR
P-value*
cEVR Non-cEVR
P-value
 n
Change from
baseline n
Change from
baseline n
Change from
baseline n
Change from
baseline
Neutrophil count

Week 4 228 )1.8 ± 1.35 1246 )2.0 ± 1.39 – 801 )2.1 ± 1.38 673 )1.8 ± 1.38 –
Week 12 230 )1.9 ± 1.77 1236 )2.0 ± 1.65 0.7969 826 )2.2 ± 1.52 640 )1.8 ± 1.82 0.0003
Platelet count

Week 4 233 )56.7 ± 43.80 1243 )47.2 ± 46.90 – 805 )53.5 ± 46.75 671 )43.0 ± 45.68 –
Week 12 231 )66.4 ± 46.80 1234 )66.1 ± 49.73 0.4846 824 )70.7 ± 50.74 641 )60.2 ± 46.68 0.0859
Haemoglobin concentration
§
Week 4 241 )2.6 ± 1.80 1300 )2.7 ± 1.94 – 836 )2.6 ± 1.86 705 )2.8 ± 1.99 –
Week 12 239 )3.2 ± 1.74 1279 )3.2 ± 1.84 0.3827 835 )3.2 ± 1.71 683 )3.2 ± 1.96 0.0160
ANCOVA, analysis of covariance; cEVR, complete early virologic response; RVR, rapid virologic response; SD, standard
deviation. Level of statistical signiﬁcance for haematologic analysis set at 0.05. *P-value for between RVR and non-RVR group
change from baseline at week 12 based on ANCOVA with baseline values and responder group as covariates.
P-value for
between cEVR and non-cEVR group change from baseline at week 12 based on ANCOVA with baseline values and responder
group as covariates.
·10
3/lL, mean ± SD.
§g/dL, mean ± sd.
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144 M. Rodriguez-Torres et al.ethnicity which accounted for 50% of the LATINO study
population [13]. Beyond the known factors (such as black or
Latino ethnicity or having a large proportion of patients with
a high baseline viral load), other unknown factors (such as
differences between studies in time effects or improvements
in HCV treatment practices over time) and variables such as
different peginterferon and ribavirin dose adjustment
protocols may have contributed to individual study being a
predictive factor.
Limited data have been published regarding the factors
associated with RVR and cEVR. A few studies have shown
that in patients receiving peginterferon alfa plus ribavirin,
lower viral load, younger age, lower body weight and
absence of advanced ﬁbrosis may be associated with a RVR
[8,19–21]. Jensen et al. [8] conducted a post hoc analysis of
216 HCV genotype 1-infected patients randomized to
24 weeks of treatment with peginterferon alfa-2a 180 lg/
week plus ribavirin either 800 mg/day (low dose) or 1000/
1200 mg/day (standard dose), and showed that baseline
viral load was a signiﬁcant predictor of RVR. Although the
overall RVR rate was 23.6%, patients with baseline HCV
RNA <200 000 IU/mL, 200 000–600 000 IU/mL and
>600 000 IU/mL had RVR rates of 49.1%, 26.0% and
9.2%, respectively. Statistical analysis showed that, relative
to patients with baseline HCV RNA >600 000 IU/mL, those
patients with HCV RNA <200 000 IU/mL (OR: 9.7; 95% CI
4.2–22.5; P < 0.0001) or 200 000–600 000 IU/mL (OR:
3.6; 95% CI 1.5–9.1; P = 0.0057) were signiﬁcantly more
likely to achieve RVR. Overall, SVR rates were considerably
higher in patients who achieved RVR than in those patients
who did not (89% vs 19%), and RVR was a signiﬁcant pre-
dictor of SVR (OR: 23.7; 95% CI 9.1–61.7; P < 0.0001). In
addition, patients infected with HCV subtype 1b were more
likely to achieve RVR than those patients infected with HCV
subtype 1a (OR: 1.8; 95% CI 0.9–3.7; P = 0.095). A lack of
RVR was also associated with liver ﬁbrosis or cirrhosis. More
recently, in a multicenter study conducted in the south of
Italy, 696 HCV genotype 1-infected patients were random-
ized to treatment with peginterferon alfa-2a or alfa-2b, each
plus ribavirin, for either 48 weeks or for an individualized
duration based on the time at which HCV RNA undetect-
ability was ﬁrst achieved [20]. In univariate analysis, young
age (P = 0.004), low baseline viral load (P = 0.0001) and
ﬁbrosis stage £2( P = 0.0001) were associated with RVR. In
multivariate analysis, HCV RNA levels <400 000 IU/mL
(OR: 2.27; 95% CI 1.49–3.41) and absence of advanced
ﬁbrosis (OR: 1.40; 95% CI 1.15–1.64) were independently
associated with achieving a RVR. Lower baseline viral load
(<400 000 IU/mL) was also the only signiﬁcant factor
associated with a RVR (OR: 3.052; 95% CI 1.706–5.458) in
200 previously untreated Taiwanese patients infected with
HCV genotype 1 who were randomized to treatment with
peginterferon alfa-2a plus ribavirin for either 24 or
48 weeks [21]. While our results are in agreement with
these studies, we believe the analysis reported here is the ﬁrst
to include an ethnically diverse cohort that is representative
of the general CHC population.
Haematologic adverse effects are relatively common when
interferons are combined with ribavirin [22] and can also
reﬂect a patients response to therapy. In patients receiving
peginterferon/ribavirin, haematologic changes can be con-
sidered a marker of pharmacodynamic effects, and may
correlate with anti-HCV activities. Similarly, a lack of a
haematologic effect may indicate a poor response to therapy.
Indeed, it has recently been reported that null virologic
response to combination therapy is associated with a blunted
haematologic response, suggesting null responders are
resistant to interferon therapy [10]. In our analysis, neu-
trophil counts, platelet counts and haemoglobin concentra-
tions decreased from baseline to weeks 4 and 12 in all
groups. While there was no difference in haematologic
response between the RVR and non-RVR groups, signiﬁ-
cantly greater decreases in haematologic parameters at week
12 were shown in patients who achieved cEVR when com-
pared with those patients who did not achieve cEVR. The
absence of any observable difference in haematologic side-
effects between the RVR and non-RVR groups may be due to
the smaller proportion of patients achieving RVR. Alterna-
tively, it could be due to the nadir of haematologic adverse
events occurring later than 4 weeks (6–8 weeks) [12]. In
addition, the bodys ability to mount a haematologic prolif-
eration response may have been able to compensate during
the early phase of therapy, thus masking the pharmacody-
namic effects of the treatment. The observed blunted
response to combination therapy in the non-cEVR group
suggests that patient factors may be partly responsible for
the individual variability in the systemic response to pegin-
terferon and/or ribavirin. Analysis of these patient factors
may prove useful in improving treatment outcomes, as well
as further our understanding of the pharmacokinetic/phar-
macodynamic relationship between drug dose and antiviral
response. For example, patients who required dose
reductions may be more likely to be responders than
non-responders, thus suggesting that antiviral response and
haematologic effects are, in essence, the pharmacodynamic
effects of interferons and ribavirin. Furthermore, it may also
reﬂect a different pharmacokinetic proﬁle in these patients,
as well as indirectly correlate with adherence and total
exposure [23,24].
In the current analysis, 16% of patients achieved RVR.
This rate is lower than the rates reported in other studies
[8,20,21] and is likely due to the number of studies in this
analysis that were enriched with patient populations that
are considered more difﬁcult to treat. For example, patients
with viral loads >400 000 and >800 000 IU/mL comprised
81% and 70% of the total study population, respectively;
black patients and white Latino patients comprised 30%,
which is reﬂective of the general CHC population. Further-
more, the heterogeneous characteristics of the patients
among the ﬁve studies included in this analysis are also
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(7–23%). In fact, in the two trials with the lowest RVR rates,
the majority of patients were black [3] or had a high baseline
viral load (>800 000 IU/mL) [12]. In contrast, the study
with the highest RVR rate had a relatively small proportion
of patients with poor prognostic markers [1]. Thus, by
including a diverse range of populations that more closely
represents the prevalence distribution of HCV infection in the
United States, our analysis provides a meaningful assessment
of the virologic response rates to treatment with peginter-
feron alfa-2a plus ribavirin, and underscores the need to
develop more effective treatment strategies for these patients.
In this retrospective analysis, we demonstrated that
baseline and on-treatment factors, including lower serum
HCV RNA concentration, higher ALT quotient, absence of
cirrhosis, younger age, white non-Latino ethnicity and daily
on-treatment ribavirin dose >13 mg/kg, were independently
associated with achieving RVR and cEVR in patients infected
with HCV genotype 1 and treated with peginterferon alfa-2a
plus ribavirin for 48 weeks. There is a need to improve
further the efﬁcacy of combination therapy, as well as limit
the associated side-effects and healthcare costs, especially in
those patient populations considered difﬁcult to treat. Opti-
mizing the antiviral response is crucial for accomplishing
these goals. Since ribavirin dose is one of the only modiﬁable
factors identiﬁed in this analysis that is associated with an
increase in RVR and cEVR, physicians may be advised to
maintain a higher ribavirin dose to increase the likelihood of
achieving SVR. Thus, identifying the predictors of response
to peginterferon alfa-2a plus ribavirin therapy and tailoring
treatment regimens for individual patients based on their
risk proﬁle may be one approach for achieving maximum
antiviral response. These ﬁndings will need to be supported
by large, prospective clinical studies that are designed to
evaluate whether SVR rates can be increased by modifying
baseline or on-treatment factors.
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